Kentucky Retirement Systems Insurance Trust Fund Has Cut Celgene (CELG) Stake By $328,321; Aristotle Capital Boston Has Boosted Team (TISI) Stake

August 12, 2018 - By Matthew Richard

Celgene Corporation (NASDAQ:CELG) Logo

Aristotle Capital Boston Llc increased Team Inc (TISI) stake by 62.83% reported in 2018Q1 SEC filing. Aristotle Capital Boston Llc acquired 445,662 shares as Team Inc (TISI)’s stock rose 17.83%. The Aristotle Capital Boston Llc holds 1.15M shares with $15.88M value, up from 709,329 last quarter. Team Inc now has $694.21 million valuation. The stock increased 1.98% or $0.45 during the last trading session, reaching $23.15. About 639,897 shares traded or 71.39% up from the average. Team, Inc. (NYSE:TISI) has declined 18.02% since August 12, 2017 and is downtrending. It has underperformed by 30.59% the S&P500. Some Historical TISI News: 08/05/2018 – Team Inc 1Q Adj Loss/Shr 58c; 13/03/2018 – Team Inc 4Q Loss/Shr 32c; 15/03/2018 – Team Inc Closes Below 200-Day Moving Average: Technicals; 15/05/2018 – Encompass Capital Advisors Buys New 1.6% Position in Team Inc; 13/03/2018 – Team Inc 4Q Adj EPS 43c; 13/03/2018 – Team Inc 4Q Rev $316.3M; 09/03/2018 – TISI CREDIT AMENDMENT ELIMINATES TOTAL LEVERAGE RATIO COVENANT; 08/05/2018 – Team Inc 1Q Loss/Shr 60c; 04/05/2018 – Victory Capital Buys New 4.5% Position in Team Inc; 05/03/2018 Team Inc Forms Golden Cross: Technicals

Kentucky Retirement Systems Insurance Trust Fund decreased Celgene Corp (CELG) stake by 17.64% reported in 2018Q1 SEC filing. Kentucky Retirement Systems Insurance Trust Fund sold 3,689 shares as Celgene Corp (CELG)’s stock declined 18.51%. The Kentucky Retirement Systems Insurance Trust Fund holds 17,220 shares with $1.54M value, down from 20,909 last quarter. Celgene Corp now has $64.15 billion valuation. The stock decreased 0.77% or $0.71 during the last trading session, reaching $91.21. About 3.25 million shares traded. Celgene Corporation (NASDAQ:CELG) has declined 32.65% since August 12, 2017 and is downtrending. It has underperformed by 45.22% the S&P500. Some Historical CELG News: 16/04/2018 – In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN); 14/05/2018 – Celgene at American Society of Clinical Oncology Meeting Jun 3; 23/05/2018 – MERCK & CO – SUBMITTED SBLA FOR KEYTRUDA IN COMBINATION TO U.S. FDA AND NEW DATA WILL BE SHARED WITH AGENCY; 16/04/2018 – OPDIVO PLUS LOW-DOSE YERVOY COMBINATION REDUCES RISK OF PROGRES; 16/04/2018 – Dynavax Reports Interim Data for SD-101 in Combination With KEYTRUDA(R) (pembrolizumab) in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck; 14/05/2018 – HHS Secretary Azar talks about more brass knuckle tactics on drug prices, but investors shrug it off again $CELG +1%; 18/04/2018 – BRISTOL-MYERS SQUIBB – OPDIVO SUBMISSION BASED ON SAFETY AND EFFICACY DATA FROM SCLC COHORT OF PHASE 1/2 CHECKMATE -032 TRIAL; 15/05/2018 – Rexahn Phase 2a Combination Study of RX-3117 and Abraxane in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage; 24/05/2018 – CELGENE CORP – REMAINING AUTHORIZATION WILL BE USED IN CONTINUING OPEN-ENDED PROGRAM EFFECTIVE IMMEDIATELY; 27/04/2018 – ADVANTAGENE – COLLABORATION TO EVALUATE SAFETY, EFFICACY OF CO’S INVESTIGATIONAL GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY COMBINED WITH BRISTOL’S OPDIVO

Since March 16, 2018, it had 1 insider buy, and 0 insider sales for $29,872 activity. BOANE GREG L bought $29,872 worth of stock or 2,015 shares.

Investors sentiment increased to 1.54 in Q1 2018. Its up 0.44, from 1.1 in 2017Q4. It improved, as 16 investors sold TISI shares while 32 reduced holdings. 18 funds opened positions while 56 raised stakes. 36.02 million shares or 6.53% more from 33.82 million shares in 2017Q4 were reported. 212,871 were accumulated by Sterling Cap Management Limited Co. Moreover, Goldman Sachs Grp Inc Inc has 0% invested in Team, Inc. (NYSE:TISI) for 113,876 shares. State Teachers Retirement Systems has 11,987 shares for 0% of their portfolio. Aristotle Cap Boston, a Massachusetts-based fund reported 1.15M shares. Tiaa Cref Inv Mgmt Ltd Liability Corporation holds 136,754 shares or 0% of its portfolio. Massmutual Trust Fsb Adv holds 0% or 357 shares in its portfolio. Bbva Compass Fincl Bank has invested 0.01% in Team, Inc. (NYSE:TISI). Sei reported 0.01% of its portfolio in Team, Inc. (NYSE:TISI). Pub Employees Retirement Of Ohio stated it has 3,333 shares or 0% of all its holdings. American Group holds 0% or 18,711 shares in its portfolio. Victory Capital Inc has 1.34M shares for 0.04% of their portfolio. Bard Assocs has invested 0.52% in Team, Inc. (NYSE:TISI). Ls Invest Advisors Ltd Company invested 0% in Team, Inc. (NYSE:TISI). Cornerstone Advsr Inc reported 0% of its portfolio in Team, Inc. (NYSE:TISI). Teton Advsrs reported 0.45% stake.

More news for Team, Inc. (NYSE:TISI) were recently published by: Globenewswire.com, which released: “Team, Inc. Reports Second Quarter 2018 Results” on August 07, 2018. Globenewswire.com‘s article titled: “Team, Inc. Schedules Second Quarter 2018 Earnings Conference Call for Wednesday, August 8, 2018 at 10:00 am …” and published on July 27, 2018 is yet another important article.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “Celgene (CELG) Q2 Earnings: Disappointment in Store?” on July 23, 2018, also Investorplace.com with their article: “5 Top Stock Trades for Friday — Buy Yelp, Roku After Earnings Surge?” published on August 09, 2018, Benzinga.com published: “Celgene Q2 Earnings Preview” on July 25, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: 247Wallst.com and their article: “Why Have Short Sellers Backed Off Major Biotechs?” published on August 10, 2018 as well as Benzinga.com‘s news article titled: “Inspired By Tesla: RBC Speculates On Go-Private Scenario For Celgene” with publication date: August 09, 2018.

Investors sentiment decreased to 0.79 in Q1 2018. Its down 0.04, from 0.83 in 2017Q4. It is negative, as 120 investors sold CELG shares while 470 reduced holdings. 106 funds opened positions while 363 raised stakes. 513.18 million shares or 8.59% less from 561.38 million shares in 2017Q4 were reported. Philadelphia owns 1.38% invested in Celgene Corporation (NASDAQ:CELG) for 185,711 shares. Invest House Ltd Company stated it has 0.78% of its portfolio in Celgene Corporation (NASDAQ:CELG). Tnb Finance reported 33,219 shares or 0.53% of all its holdings. Fisher Asset Management Lc has 0.04% invested in Celgene Corporation (NASDAQ:CELG) for 361,949 shares. 1.58M are held by Old Mutual Invsts (Uk). Affinity Advsr Limited Liability Com has 95,492 shares. First Mercantile Trust reported 0.14% in Celgene Corporation (NASDAQ:CELG). Legal & General Public Ltd Llc invested in 3.55M shares or 0.24% of the stock. Chicago Equity Ptnrs Ltd Com holds 0.14% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 49,245 shares. Dock Street Asset Mgmt has 3,853 shares for 0.13% of their portfolio. Fulton Savings Bank Na owns 30,579 shares. Natixis Advsr LP reported 143,035 shares stake. Capital Inv Advsr Llc has 2,802 shares. Jpmorgan Chase has invested 0.1% in Celgene Corporation (NASDAQ:CELG). Two Sigma Securities Limited Liability invested in 35,289 shares or 0.02% of the stock.

Among 17 analysts covering Celgene (NASDAQ:CELG), 12 have Buy rating, 0 Sell and 5 Hold. Therefore 71% are positive. Celgene had 22 analyst reports since February 13, 2018 according to SRatingsIntel. The company was maintained on Wednesday, April 4 by RBC Capital Markets. The rating was maintained by BMO Capital Markets with “Outperform” on Wednesday, February 28. Morgan Stanley maintained Celgene Corporation (NASDAQ:CELG) rating on Friday, April 13. Morgan Stanley has “Equal-Weight” rating and $93 target. The rating was maintained by Cantor Fitzgerald with “Hold” on Thursday, May 31. Robert W. Baird maintained it with “Hold” rating and $92.0 target in Wednesday, February 28 report. Morgan Stanley maintained the shares of CELG in report on Friday, July 13 with “Equal-Weight” rating. The stock of Celgene Corporation (NASDAQ:CELG) earned “Outperform” rating by Credit Suisse on Wednesday, February 28. Leerink Swann maintained the shares of CELG in report on Monday, May 7 with “Buy” rating. Oppenheimer maintained the shares of CELG in report on Friday, May 25 with “Buy” rating. The stock of Celgene Corporation (NASDAQ:CELG) has “Equal-Weight” rating given on Monday, May 7 by Morgan Stanley.

Since February 15, 2018, it had 1 buy, and 5 selling transactions for $6.21 million activity. 13,370 shares were sold by MARIO ERNEST, worth $1.26 million. Shares for $1.40 million were sold by LOUGHLIN JAMES J. CASEY MICHAEL D sold $1.02 million worth of Celgene Corporation (NASDAQ:CELG) on Thursday, June 7. 18,500 Celgene Corporation (NASDAQ:CELG) shares with value of $1.77M were sold by KAPLAN GILLA. 1,208 shares were bought by Alles Mark J, worth $99,784 on Tuesday, May 8.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts